Clinical evaluation and reproducibility of the Pastorex *Aspergillus* antigen latex agglutination test for diagnosing invasive aspergillosis


Abstract

**Aims**—The performance of the Pastorex *Aspergillus* antigen latex agglutination test for the detection of galactomannan in sera of patients at risk for invasive aspergillosis was evaluated, and the impact of storage on the reproducibility of the antigen titre was tested.

**Methods**—During a one year period, 392 serum samples were obtained from 46 patients at risk for invasive aspergillosis and tested for the presence of galactomannan using an *Aspergillus* latex agglutination test (Pastorex). Twenty three positive serum samples which had been stored at −20°C for 2–16 months were retrospectively retested. Furthermore, two positive serum samples were stored at −20°C and −70°C and prospectively tested at three month intervals for a period of 15 months.

**Results**—The Pastorex *Aspergillus* test was positive in eight patients with microbiological, radiological, or histological evidence for invasive aspergillosis, but was negative in the initial serum sample from five of these patients. In two patients with histological evidence for invasive aspergillosis no positive reaction was found in six samples. Six of 13 (45%) serum samples which had been stored at −20°C for longer than six months had lost reactivity, while one of 10 (10%) samples had lost reactivity when stored up to six months. Two serum samples which had been stored at −20°C and −70°C and prospectively retested at three month intervals for 15 months, maintained stable antigen titres.

**Conclusions**—The Pastorex *Aspergillus* test is too insensitive to diagnose invasive aspergillosis in an early stage, but may contribute to the diagnosis when cultures remain negative and serial samples are obtained. To maintain a good reproducibility, serum samples should be stored at −70°C when the period of storage exceeds six months.


Keywords: Aspergillosis, diagnosis, galactomannan, serology.

Invasive aspergillosis is a serious opportunistic infection with a high mortality rate in patients with compromised host defences. Since early treatment is associated with a reduced mortality rate,¹ reliable diagnostic tests capable of detecting invasive aspergillosis in an early stage are of great importance. Early diagnosis is, however, extremely difficult. Therefore tests have been developed to detect *Aspergillus* antigens in body fluids.² Several serological tests to detect antigenemia have been used, including an enzyme linked immunoassay and a radioimmunoassay using purified galactomannan.³,⁴ Monoclonal antibodies raised against galactomannan⁵ are the basis of a rapid commercial latex agglutination test (Pastorex *Aspergillus*, Sanofi Diagnostics Pasteur, Marnes-La-Coquette, France) on serum for detection of circulating antigen. This test, which has been applied in many hospitals, yielded sensitivities up to 95% for patients with proven invasive aspergillosis,⁶ but has been reported to be of limited value because results became negative when testing was repeated after storage.⁷,⁸ Here, we report our experience with the Pastorex *Aspergillus* test in patients at risk for invasive aspergillosis, and the results of a study we conducted to determine the impact of the duration of storage and repeated freezing and thawing on the antigen titre.

**Methods**

During a one year period, 392 serum samples were obtained from 46 patients at risk for invasive aspergillosis. At least two serum samples per patient were collected and processed within 24 hours of collection, and frozen at −20°C until retesting. Testing of all samples was performed by one technician and according to the manufacturer’s instructions. Titration of positive samples was performed by successive twofold dilutions (1:2 to 1:32) in glycine dilution to buffer. To determine the impact of storage on the antigen titre, all positive serum samples were retested retrospectively.

In addition, a prospective study was performed with two positive serum samples obtained from one patient with a histologically proven disseminated infection with *A fumus*. The impact of repeated freezing and thawing was studied by storing 6 ml of each serum at −20°C and −70°C, respectively, for a total period of 15 months. At three month intervals the samples were thawed and the agglutination reaction was performed. Positive agglutination reactions were titrated. The impact of storage on the antigen titre was studied by dividing the remainder of the two serum samples into 20
Table 1  Clinical evaluation and reproducibility of Pastorex Aspergillus latex agglutination test in patients at risk for invasive aspergillosis

<table>
<thead>
<tr>
<th>Patient No</th>
<th>Age/sex</th>
<th>Underlying disease</th>
<th>Postmortem diagnosis</th>
<th>No of samples tested/ No of positive samples</th>
<th>Time</th>
<th>No of samples retested/ No of positive samples</th>
<th>Time</th>
<th>Time between first/second test (months)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>16/F</td>
<td>NHL, BMT</td>
<td>Aspergillus in bronchi, not invasive</td>
<td>6/1</td>
<td>1:4</td>
<td>1/0</td>
<td>neg</td>
<td>16</td>
</tr>
<tr>
<td>2</td>
<td>58/M</td>
<td>Hepatocellular carcinoma</td>
<td>Mycotic necrotising bronchopneumonia</td>
<td>3/2</td>
<td>1:4</td>
<td>2/2</td>
<td>1:2</td>
<td>15</td>
</tr>
<tr>
<td>3</td>
<td>36/F</td>
<td>AML</td>
<td>ND</td>
<td>1/1</td>
<td>1:4</td>
<td>1/1</td>
<td>neg</td>
<td>14</td>
</tr>
<tr>
<td>4</td>
<td>45/F</td>
<td>Kahler, BMT</td>
<td>Survived</td>
<td>18/2</td>
<td>1:8</td>
<td>1/1</td>
<td>1:4</td>
<td>11</td>
</tr>
<tr>
<td>5</td>
<td>30/M</td>
<td>AML</td>
<td>Cavitating bronchopneumonia invasive</td>
<td>22/8</td>
<td>1:4</td>
<td>8/3</td>
<td>1:1</td>
<td>9</td>
</tr>
<tr>
<td>6</td>
<td>44/F</td>
<td>AML, BMT</td>
<td>Mycotic necrotising bronchopneumonia</td>
<td>8/3</td>
<td>1:2</td>
<td>3/3</td>
<td>1:2</td>
<td>6</td>
</tr>
<tr>
<td>7</td>
<td>53/M</td>
<td>CML, BMT</td>
<td>ND</td>
<td>9/4</td>
<td>1:2</td>
<td>1/1</td>
<td>1:1</td>
<td>2</td>
</tr>
<tr>
<td>8</td>
<td>37/M</td>
<td>AIDS</td>
<td>ND</td>
<td>3/3</td>
<td>1:1</td>
<td>3/3</td>
<td>1:1</td>
<td>2</td>
</tr>
</tbody>
</table>

ND = non-Hodgkin’s lymphoma; BMT = bone marrow transplantation; AML = acute myeloid leukaemia; CML = chronic myeloid leukaemia; AIDS = acquired immunodeficiency syndrome; ND = not done.

Eppendorf tubes (300 µl). Ten tubes were stored at −20°C and 10 at −70°C for a total period of 15 months. At three month intervals two tubes stored at −20°C and two stored at −70°C were thawed. The first of each pair of samples was used to perform the agglutination reaction. When positive, the second sample was used for titration.

The Mann-Whitney test was used to determine statistical significance.

Results
A total of 392 serum samples was tested from 46 patients suspected of invasive aspergillosis. Seventy serum samples were collected from eight patients with microbiological, radiological, or histological evidence of invasive aspergillosis (table 1). Of these, 24 samples were found to be positive (titres ranged from 1:1 to 1:8). In all cases the Pastorex Aspergillus test results were interpreted in the whole clinical context of the patient. Antifungal therapy was not given in two cases (table 1, patients Nos 2 and 4). In five cases the antigen test was negative at the time antifungal therapy was started, but became positive during treatment (table 1, patients Nos 1, 3, 5, 7, and 8). In one case (table 1, patient No. 6) antifungal therapy was initiated when the Pastorex Aspergillus test was found positive after five successive samples had been negative. Culture of a bronchoalveolar lavage performed the same day yielded A fumigatus. Two patients (acute lymphoblastic leukaemia and myelodysplastic syndrome) with histological evidence of invasive aspergillosis showed no positive reaction in six samples. We found only one false positive agglutination in a sample which arrived at the laboratory more than 48 hours after collection. Eight other samples from this patient with chronic granulomatous disease, processed within six hours of collection, were negative. A necropsy performed on this patient, who died of cardiac failure, revealed no evidence of invasive aspergillosis.

Twenty three positive samples, which had been stored at −20°C for 2–16 months, were available for retesting. The results of retesting are shown in table 1. Nine out of 10 (90%) positive serum samples, which had been stored up to six months at −20°C, showed a positive agglutination reaction when retested retrospectively, while seven of 13 (54%) samples were found positive when stored at −20°C for longer than six months (table 1; p = 0.067).

The effect of storage at −20°C and −70°C and of repetitive freezing and thawing of serum on the galactomannan antigen titre is shown in table 2.

Table 2  Effect of storage on Aspergillus antigen titre. A: Storage at −20°C and −70°C. Serum samples were thawed before every agglutination test. B: Storage at −20°C and −70°C. Serum samples were stored until antigen titre was determined. Serum 1 (S1) and 2 (S2) were taken 3 days and 1 day, respectively, before death due to invasive aspergillosis

<table>
<thead>
<tr>
<th>Storage</th>
<th>S1 (−20°C)</th>
<th>S2 (−70°C)</th>
<th>S1 (−20°C)</th>
<th>S2 (−70°C)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Time between tests (months)</td>
<td>0</td>
<td>1:8</td>
<td>1:32</td>
<td>1:8</td>
</tr>
<tr>
<td>A</td>
<td>1:8</td>
<td>1:16</td>
<td>1:8</td>
<td>1:16</td>
</tr>
<tr>
<td>B</td>
<td>1:8</td>
<td>1:16</td>
<td>1:8</td>
<td>1:16</td>
</tr>
<tr>
<td>6</td>
<td>1:8</td>
<td>1:16</td>
<td>1:8</td>
<td>1:16</td>
</tr>
<tr>
<td>9</td>
<td>1:8</td>
<td>1:16</td>
<td>1:8</td>
<td>1:16</td>
</tr>
<tr>
<td>12</td>
<td>1:8</td>
<td>1:16</td>
<td>1:8</td>
<td>1:16</td>
</tr>
<tr>
<td>15</td>
<td>1:8</td>
<td>1:16</td>
<td>1:8</td>
<td>1:16</td>
</tr>
</tbody>
</table>

Discussion
Since serial antigen determination has been shown to be of great importance,5 we obtained

Discussion
Since serial antigen determination has been shown to be of great importance,5 we obtained
as many serum samples as possible from patients at risk for invasive aspergillosis. Several investigators have reported the use of a number of methods to detect circulating Aspergillus antigen in body fluids. Although antigen detection appears to be highly specific, the sensitivity of the tests used until now has been quite low. The Pastorex Aspergillus test is the only antigen test which is commercially available, but its use to diagnose invasive aspergillosis in an early stage is controversial. Several investigators have reported a high sensitivity of this test, up to 95%, and found that the Pastorex test allowed diagnosis of invasive aspergillosis to be made earlier in 68% of cases when compared to conventional methods. However, other studies have shown that the Pastorex Aspergillus test had a low sensitivity and a poor positive predictive value in necropsy proven cases of invasive aspergillosis. Our results also indicate that the Pastorex Aspergillus test is too insensitive to diagnose invasive aspergillosis in an early stage, but may contribute in the diagnosis if cultures remain negative and serial serum samples are obtained.

Poor reproducibility of the Pastorex Aspergillus test has been reported, which can make the interpretation of positive agglutination results difficult. Warnock et al. retested 10 positive serum samples which had been stored for three days to 10 months at \(-30^\circ\)C, and found that all samples had become negative, and Knight et al. retested 32 positive samples with a different batch and found loss of reactivity in 14 samples. However, these reactions could have been false positive as the manufacturer's instructions were not followed. In the present study, serum samples which had been stored at \(-20^\circ\)C for more than six months tended to lose reactivity. Although, because of the limited number of positive samples available, the difference was not statistically significant in comparison to serum samples stored for less than six months, it shows a trend towards loss of reactivity when serum samples are stored at \(-20^\circ\)C for long periods of time. Also, the titre found at retesting tended to be lower when the period of storage became longer.

The serum samples which were stored at \(-20^\circ\)C and \(-70^\circ\)C and prospectively retested at three month intervals were all found to be positive with stable antigen titres. Repeated freezing and thawing of these serum samples (table 2, A) did not appear to have an effect on the reproducibility. However, to maintain a good reproducibility in the Pastorex Aspergillus test, we recommend that serum samples should be stored at \(-70^\circ\)C when the period of storage exceeds six months.

In the absence of better commercial antigen detection, the Pastorex Aspergillus test remains useful, although a better test needs to be developed. Other techniques, including DNA based assays, may contribute in the diagnosis of invasive aspergillosis in an early stage. Several investigators have reported the use of the polymerase chain reaction (PCR) for the detection of Aspergillus DNA in BAL fluid. The PCR showed a very high sensitivity and specificity in patients at high risk for invasive aspergillosis. However, the value of the PCR in the diagnosis of this condition remains to be established and prospective evaluations are now being performed.

The diagnosis of invasive aspergillosis is difficult and demands a multidisciplinary approach. The implementation and combination of novel or improved methods, for example PCR and antigen detection, to diagnose invasive aspergillosis in an early stage or in guiding treatment may improve the clinical outcome of this disease.

Clinical evaluation and reproducibility of the Pastorex Aspergillus antigen latex agglutination test for diagnosing invasive aspergillosis.

P E Verweij, A J Rijs, B E De Pauw, A M Horrevorts, J A Hoogkamp-Korstanje and J F Meis

doi: 10.1136/jcp.48.5.474

Updated information and services can be found at:
http://jcp.bmj.com/content/48/5/474

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/